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Abstract  
Background 
Epilepsy is a major cause of morbidity and mortality in meningioma patients. The aims of 
this study were to determine which factors predispose meningioma patients to developing 
perioperative seizures and to understand the impact of antiepileptic drugs. 
Methods  
Patients treated for a histologically-confirmed intracranial meningioma at the authors’ 
institution between 2010 and 2015 were retrospectively examined. Clinical and imaging data 
were assessed. Multivariate analysis was performed using binary logistic regression. The 
effect of antiepileptic treatment was assessed using survival analysis.  
Results  
Two hundred and eighty-three patients met the selection criteria; seizures were present in 68 
preoperatively (24%) and in 48 patients (17%) following surgery. Of the 68 with preoperative 
seizures, 19 continued to have them, whereas de-novo seizures arose postoperatively in 29 
seizure-naïve patients. Risk factors of postoperative seizures were convexity location 
(OR=2.05 [95% CI=1.07-3.98], p=0.030), fronto-parietal location (OR=4.42 [95% CI= 1.49-
13.16], p=0.007) and preoperative seizures (OR=2.65 [95% CI=1.37-5.24], p=0.005). The 
two locations, in addition to the presence of midline shift on preoperative imaging (OR=4.15 
[95% CI=1.54-11.24], p=0.005), were significantly correlated with postoperative seizures in 
seizure-naïve patients. Antiepileptic treatment in patients with those risk factors reduced the 
possibility of seizures at any time point within the 1st year postoperatively by approximately 
40%, although this did not meet statistical significance.   
 
 
 
4 
 
Conclusion 
Prophylactic antiepileptic treatment might be warranted in seizure-naïve meningioma patients 
with ≥1 risk factor. High-quality randomised controlled trials are required to verify those 
factors and to define the role of antiepileptics in meningioma practice.   
Key words  
Antiepileptic drugs; Epilepsy; Meningioma; Post-operative seizure 
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Introduction    
Whilst focal neurological deficits and incidental discovery account for the majority of new 
diagnoses of intracranial meningioma (1, 2), approximately a third of patients present with 
focal epilepsy (3). Antiepileptic drugs (AEDs) are indicated for the treatment of brain 
tumour-related seizures, however, there still remains no consensus on whether prophylactic 
AEDs should be prescribed in seizure-naïve patients to prevent the development of 
postoperative seizures (4). Epilepsy in meningioma patients is a major cause of morbidity and 
mortality (5, 6), but the rate at which new seizures develop in patients undergoing 
meningioma surgery varies, and the efficacy of AEDs in reducing post-operative seizure rates 
remains questionable (7, 8). Furthermore, drug-related side effects, which can impair quality 
of life (QoL) and neurocognitive function (NCF), occur in up to half of patients (5, 9, 10).  
Therefore, appropriate selection of patients at risk of developing epilepsy in the peri-
operative period and who might benefit from AED treatment for meningioma resection is 
important.  
Objectives 
To investigate the risk factors associated with developing peri-operative epilepsy in 
meningioma patients, and to determine whether AEDs reduce the risk of postoperative 
seizures.  
Methods 
Patient selection  
Data for patients who underwent craniotomy and resection of a histologically-confirmed 
intracranial meningioma between Jan 2010 and Dec 2015 were collected retrospectively. 
Eligibility criteria were as follows: (i) surgery for newly-diagnosed meningioma, (ii) a 
follow-up period ≥12 months, (iii) pre- and postoperative imaging available. 
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Clinical and radiological characteristics 
Clinical information was obtained from the medial records. Extracted preoperative data 
included patient demographics, seizure status and semiology (categorised according to the 
International League Against Epilepsy [ILAE] 2017 classification (11)), the use of AEDs 
(treatment or prophylaxis), clinical presentation (headache and focal neurological deficits), 
and the Eastern Cooperative Oncology Group performance status (ECOG). Radiological 
factors, recorded using the Carestream Vue picture archiving and communication system 
(PACS) version 11, included tumour location and volume, peritumoural signal change, 
midline shift, and calcification. Tumour volume was determined by manual segmentation on 
gadolinium-enhanced T1-weighted MRI scans. Peritumoural signal change was assessed in 
relation to tumour volume on T2-weighted MRI and grouped as follows: 0-5%, 6-33%, 34-
66% and 67-100%. Zero to 5% was defined as absent oedema (based on the Visually 
AcceSAble Rembrandt Images [VASARI] MR features for gliomas (12)).  
Tumours were classified according to the WHO 2007 system. Extent of resection (as 
recorded by the neurosurgeon in the operative notes), the presence of residual tumour on 
contrast-enhanced postoperative MRI, post-craniotomy complications (hydrocephalus, CNS 
infection, clinically symptomatic haemorrhage and radiological haemorrhage), and the 
incidence of postoperative seizures were recorded. Gross total resection (GTR) was defined 
as Simpson grades I–III, whilst subtotal resection (STR) was defined as grades IV–V. For 
patients who had postoperative seizures, time to first seizure was calculated from the date of 
surgery to the first clinical encounter where seizure signs and symptoms were reported and 
judged by the attending neurosurgeon/neurologist to have constituted an epileptic seizure. 
Complete seizure control, which equates to a postoperative ILAE outcome of 1 (13), was 
determined at 12 months following this encounter.  
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Data analysis  
Data was analysed using SPSS v24.0 (IBM, Armonk, NY, USA). 
Patients were stratified based on the presence of preoperative seizures. Clinical correlates of 
preoperative epilepsy were accordingly determined using binary logistic regression (BLR), 
incorporating only factors with a significance level < 0.05 on univariate analysis, which was 
performed using Pearson’s Chi-square test for categorical variables and the Mann–Whitney U 
test for continuous variables. Odds ratios (ORs) with 95% confidence intervals (CI) were 
calculated to assess factors’ effect size. Risk factors of postoperative seizures were similarly 
determined in all patients, and in seizure-naïve patients.  
A forward stepwise selection procedure was utilised to determine the model of best fit. Model 
assumptions were tested by examination of residuals and the overall fit was assessed using 
the Hosmer and Lemeshow (H-L) test and the area under the receiver operating characteristic 
(ROC) curve (AUC). 
The effect of AED therapy on postoperative seizure rates was assessed using a cox 
proportional hazards regression model. As the Driver and Vehicle Licensing agency (DVLA) 
in the United Kingdom (UK) sets the driving ban to a maximum duration of 12 months 
postoperatively in meningioma patients, time to first seizure was censored at 365 days in case 
of no-occurrence within the first 12 months (14). The model encompassed 2 factors: AED 
treatment (yes/no), and a dummy variable incorporating statistically significant variables in 
the corresponding BLR model. Model performance was assessed using the likelihood-ratio 
statistic (–2LL) and for each variable a hazard ratio (HR) was extracted with its 95% CI.   
Data validation 
For tumour volume, Bland-Altman plots were performed to assess inter- and intra-observer 
variability. The repeated measurements were carried out on a random sample of 11 patients.  
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Bivariate correlation was undertaken to assess the relationships between different factors. 
Baseline variables that proved to be significantly correlated (p<0.05) were entered as one into 
the BLR model. 
Distribution of continuous variables was examined with normally distributed variables 
expressed as mean (standard deviation [SD]) and skewed variables as median (interquartile 
range [IQR]). Statistically significant skewed variables (p<0.05) were transformed into their 
natural logs before being inputted into the BLR model.  
Meningioma surgery and AED practice 
No protocol for AED treatment is available at the authors’ institution and practices are based 
on surgeon preference. Management decisions for meningioma are by consensus within the 
neuro-oncology multidisciplinary team. Patients are considered for surgery if symptomatic or 
asymptomatic and showing evidence of meningioma growth on surveillance imaging. Age, 
performance status and comorbidities are also considered. Of note, none of the patients 
included in this study were subject to preoperative embolisation.  
Results  
Study population 
Demographic and clinical data are summarised in Table 1. Two hundred and eighty-three 
patients met the inclusion criteria. Sixty-eight patients presented with seizures, 62 of whom 
received preoperative AED treatment. The remaining 215 patients were seizure-naïve at 
presentation and 19 received prophylactic AED treatment (Fig. 1). Postoperative seizures 
were observed in 17% (48/283). Median time to seizure occurrence was 58 days (IQR=442). 
There was one postoperative death due to epilepsy in a 69-year old male (ECOG 0, presented 
with epilepsy and treated with lamotrigine). Following surgical resection of a frontal 
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convexity meningioma, the patient had a focal to bilateral seizure on day 5 after surgery and 
subsequently died. No other seizure-related mortalities occurred.  
Predictors of preoperative seizures 
Univariate analysis (Table 1) revealed parafalcine and parietal tumour locations to be 
associated with preoperative seizures (p=0.023, p<0.001), however, the two factors were 
linked on bivariate correlation (p=0.022) and were therefore incorporated as one variable into 
the BLR model. The presence of peritumoural signal intensity (6-100%) and the absence of 
focal neurological deficits were also correlated with preoperative seizures (p<0.001, 
p<0.001).  
All three factors remained significant in the BLR model: parietal-parafalcine location 
(OR=2.81 [95% CI=1.44-5.46], p=0.002), peritumoural signal change (OR=5.10 [95% CI= 
2.49-10.52], p<0.001) and the absence of focal neurological deficits (OR=5.55 [95% 
CI=2.63-11.11], p<0.001). 
Predictors of postoperative seizures  
Whole study population  
On univariate analysis, convexity location (p=0.014), fronto-parietal location (p=0.003), 
preoperative seizures (p=0.006) and the presence of peritumoural signal intensity (6-100%) 
(p=0.022) were significantly associated with postoperative seizures (Table 2). The two 
meningioma locations were not correlated (p=0.19). All four factors were inserted into the 
BLR model, in which the following remained significant: convexity location (OR=2.05 [95% 
CI=1.07-3.98], p=0.030), fronto-parietal location (OR=4.42 [95% CI= 1.49-13.16], p=0.007) 
and preoperative seizures (OR=2.65 [95% CI=1.37-5.24], p=0.005). 
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Seizure-naïve patients 
Convexity location (p=0.003), fronto-parietal location (p<0.001), male sex (p=0.008), 
midline shift (p=0.028), presence of peritumoural signal intensity (6-100%) (p=0.017), 
Simpson grade I resection (p=0.020), and clinically symptomatic haemorrhage (p=0.038) 
were statistically associated with postoperative seizures on univariate analysis (Table 2). The 
median meningioma volume in postoperative-seizure patients was 63.3 cm3 as opposed to 
33.2 cm3 in patients who remained seizure-free (p=0.003). Bland-Altman plots for intra-and 
inter-observer variability of meningioma volume indicated a good level of agreement. 
Three factors remained significant in the BLR model: convexity location (OR=4.63 [95% 
CI=1.89-11.36], p<0.001), fronto-parietal location (OR=7.52 [95% CI= 2.04-27.78], 
p=0.002), and the presence of midline shift on preoperative imaging (OR=4.15 [95% CI= 
1.54-11.24], p=0.005).  
Models performance   
H-L tests for the previous three models were > 0.05 indicating a good fit (0.27-0.83). AUC 
values and plotted residuals were acceptable for the 1st and 2nd model. Parameters of the 3rd 
model were poor.  
Antiepileptic drug treatment  
The study flow chart (Fig. 1) outlines AED treatment arms and consequent seizure rates. The 
most frequently utilised AEDs were phenytoin (48.1%) and levetiracetam (25.9%). 
Prophylactic AED use in seizure-naïve patients who did not develop postoperative epilepsy 
ranged from a single dose at surgery to 1092 days (median=275 [IQR=419]). AEDs in 
patients with complete postoperative control of preoperative epilepsy, were stopped less than 
12 months after surgery in 32 (65.3%) patients, whereas 17 (34.7%) were on lifelong 
treatment (>12 months) (median=351 [IQR=1217]) (p=0.185).  
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To examine the seizure response to AEDs, two cox regression analyses were performed: the 
first encompassing the whole study population and incorporating two variables: AED 
treatment and a dummy variable (convexity * fronto-parietal * preoperative seizures). The 2nd 
model comprised seizure-naïve patients and two variables were entered: AED treatment and 
one dummy variable (convexity * fronto-parietal * midline shift). The two models performed 
well (-2LLs=0.001 and 0.004). Both dummy variables had HRs >1 (p=0.004, p=0.002) 
whereas AED treatment in both models had a HR <1, reducing adjusted seizure risk (≥ 1 risk 
factor), at any time within the 1st year postoperatively, by 38% and 37% respectively, albeit 
this did not reach statistical significance (p=0.187, p=0.451; Table 3). 
Twelve-month seizure control rates 
One hundred and seventy-eight (90.8%) seizure-naïve patients who did not receive 
prophylactic AEDs remained seizure-free 12 months after surgery. The rate was slightly 
lower for seizure-naïve patients who were prescribed AEDs (78.9%) (p=0.096). Fifty (80.6%) 
patients who had AED-treated preoperative epilepsy were free of seizures at 12 months as 
opposed to 4 (66.7%) untreated patients (p= 0.427). In total, the probability of seizure-
freedom through 12 months of follow-up was 89.8% in seizure-naïve patients and 79.4% in 
patients with preoperative epilepsy (p=0.029). These rates dropped to 86.5% and 72.1% 
respectively beyond 12 months (Fig. 1).  
Control of postoperative seizures within 12 months of their onset 
Data was available in 47 patients (1 dead) and 18 (38.3%) had poorly controlled seizures. Ten 
out of 18 (55.6%) patients with poorly controlled epilepsy had seizures preoperatively. Of the 
29 patients with controlled seizures, 8 (27.6%) patients had preoperative seizures (p=0.015). 
At this stage, AED monotherapy was being used in 11/18 (61.1%) patients with poorly 
controlled seizures.  
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Discussion  
Studies addressing perioperative seizures are important for informing driving guidance and 
QoL in operated meningioma, and to justify the use or avoidance of prophylactic AEDs. In 
this cohort of 283 patients, parietal-parafalcine location, peritumoural signal change and the 
absence of focal neurological deficits were identified as independent predictors of 
preoperative seizures. Convexity and fronto-parietal locations, and the presence of 
preoperative seizures were significantly associated with postoperative seizures, in addition to 
the presence of midline shift on preoperative imaging in seizure-naïve patients. The 
likelihood of seizure-freedom after 12 months of follow-up was 89.7% in seizure-naïve 
patients and 79.4% in patients with preoperative epilepsy.    
Risk factors of preoperative seizures  
In our study cohort, 24% of patients presented with seizures, which is higher than those rates 
of previous reports which comprised fewer non-skull base meningiomas (15, 16), and more 
specifically those located along the falx abutting the parietal lobe, a factor which retained 
significance in the BLR model pertaining to preoperative seizures.  
The presence of peritumoural signal change, indicative of vasogenic oedema, and the absence 
of focal neurological deficits preoperatively were also independently associated with 
preoperative seizures, consistent with the findings of prior papers (16-19). Oedema in 
meningioma patients is postulated to be the product of vascular endothelial growth factor-A 
and is more frequently observed in invasive subtypes of meningioma, although this did not 
prove to be the case in our study (WHO grade I: 23.2% vs. WHO grades II/III: 28%) (20, 21). 
Smaller meningiomas, although statistically insignificant, were preoperatively more 
epileptogenic, potentially causing the development of seizures before symptoms of mass 
effect, such as focal neurological deficits, manifest. We postulate that smaller slow-growing 
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meningiomas are allowed more time to disrupt the peritumoural functional environment 
driving epileptogenesis, whereas bigger relatively faster-growing meningiomas tend to 
display symptoms of mass effect before the epileptic process occurs.   
Predictive factors of postoperative seizures  
De-novo seizures occurred in 29 seizure-naïve patients (13.5%), 9 (4.2%) of which arose in 
the early postoperative period (within 1 week of surgery), which is slightly higher than the 
pooled frequency of 2.7% in a recent systematic review (11). Midline shift, previously shown 
to play a role in epilepsy development following evacuation of intracranial haemorrhages and 
resection of cerebral metastases (22, 23), was likewise independently associated with 
postoperative seizures in seizure-naïve meningioma patients.  
In keeping with previous studies (18, 24, 25), tumour location was an independent predictive 
factor. Convexity and fronto-parietal locations increased the risk of seizures arising by 2- and 
5-fold respectively, and these numbers were approximately doubled for seizure-naïve 
patients. The reason being the proximity to cortical areas which are susceptible to epilepsy-
predisposing morphological and functional alterations (26). This also holds for fronto-parietal 
meningiomas located in the vicinity of the hyperexcitable primary motor and somatosensory 
cortices, which had an associated epilepsy incidence rate of 63% in a previous study (27, 28). 
Simpson grade I resection was correlated with postoperative seizures on univariate analysis. 
Most patients with Simpson I resection were convexity meningiomas in our cohort (bivariate 
correlation, p<0.001), and these are considered more susceptible to postoperative seizures, 
therefore the association between Simpson resection and seizures is a statistical finding that is 
not clinically relevant. 
The association between peritumoural oedema and postoperative seizures was noted on 
univariate analysis, however, it did not emerge as in independent factor in the BLR model. 
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Due to the small number of patients with seizures (n=48), we did not stratify into early and 
late epilepsy. Vasogenic oedema tends to resolve within 2 weeks of surgery in 90% of the 
cases and future studies should stratify patients into early and late seizures (29).  
Do AEDs have a role in reducing seizure rates postoperatively? 
The general consensus, comprising reviews and one retired practice parameter by the 
American Academy of Neurology (AAN), is that AEDs should not be routinely used for 
prophylaxis (3, 4, 7, 8, 30), and specific guidelines for the administration of AEDs in 
meningiomas are yet to be formulated. As a result, a wide variety of AED practices are 
observed, firstly at a local level in our institute and secondly on a wider scale as the 
AANS/CNS survey demonstrated (31). AEDs in our study were only administered to 8.1% of 
seizure-naïve patients compared to 63% of surgeons prescribing AEDs almost always (31). 
This highlight, that for the time being, AEDs will continue to be prescribed in the 
neurosurgical community, despite the lack of proven benefit.  
Previous studies have devised scoring systems to guide AED prescribing including the 
STAMPE2 prognostic index (17). The limitation of such scoring systems is that it’s difficult 
to estimate the reduction rate of seizures at each level and hence, the choice of a cut-off point 
for treatment is arbitrary. Our solution to this was to model data using survival analysis, to 
estimate the effect of AEDs in patients with different combinations of independent risk 
factors in all patients and in those seizure-naïve specifically. The hazard ratios for AED 
treatment in the models equate to an approximate seizure reduction rate of 40%. Although 
this was not statistically significant, these data could help direct the administration of AEDs, 
which due to side effects and impact on QoL, should not be prescribed routinely.   
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Choice of AED and duration of treatment 
The wide variation in AED choice and duration of use in our study limits analysis of which 
drug might be most effective. Studies addressing optimal AED regimens are required, 
specifically for preoperative epilepsy patients whose seizures cease to recur for the first 2 
weeks after surgery. In our study, this was observed in 49 patients of which 32 (65.3%) were 
on AEDs for up to 12 months. Recommendations are to allow a duration of at least 2 years of 
seizure-freedom before discontinuation is attempted (32); however, this is based on AED 
trials that almost invariably exclude brain tumour patients from their populations, and 
therefore this cannot be applied to meningioma patients. The question of how long to 
continue AEDs could pragmatically be based around driving regulations, adverse events and 
quality of life. Targeting a policy of 3 or 12 months of AED administration would be 
achieved in the context of a RCT. We could not draw any meaningful conclusions to support 
the use of one drug prophylactically over others. A well-designed trial is also required to 
address this question.  
Postoperative seizure freedom  
Through 12 months of follow-up, the probabilities of seizure-freedom in seizure-naïve 
patients and preoperative epilepsy patients were approximately 90% and 80% respectively. 
Beyond 12 months, the rate in patients with preoperative epilepsy dropped to 72.1%. Within 
12 months of seizure-onset, likelihood of seizure freedom was 44.4% among subjects with 
preoperative seizures and 72.4% in patients without them. This implies that whilst an 
acceptable rate of seizure-control could be achieved in seizure-naïve patients, control of 
seizures in patients with preoperative epilepsy is more challenging. The ILAE’s definition of 
drug resistant epilepsy emphasises that treatment failure is assessed in the context of two 
trialled drugs, either in combination or as monotherapies (33). In our study, 61.1% of patients 
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with uncontrolled seizures did not meet the aforementioned criteria. Those rates therefore 
need to be further evaluated following escalation of AED treatment. 
Study limitations 
This is a retrospective study of uneven groups operated for a meningioma in a single 
institution. AED choice and duration varied across patients and drug-related side effects were 
not recorded, therefore comparisons of drugs could not be performed. Seizure types are likely 
to impact patients differently however seizure semiology postoperatively was not recorded. 
Lastly, Parameters of the three BLR models were acceptable for two and poor for the model 
pertaining to seizure-naïve patients.  
Conclusions  
Summarised in Fig. 2 are our recommendations for treatment and future research. Seizures 
and AEDs in meningioma patients have a great impact on QoL. The ability to identify 
patients at risk of seizures and to understand how AEDs augment their risk is of importance 
to clinicians and patients. Convexity and fronto-parietal locations as well as preoperative 
epilepsy are the factors most strongly related to postoperative seizures, in addition to the 
presence of a midline shift on preoperative imaging in seizure-naïve patients. AEDs could 
potentially prove beneficial in those groups of patients with an approximate seizure-reduction 
of 40%. High quality randomised controlled trials however are required to verify these factors 
and to determine whether AEDs have a definitive role in reducing seizure rates 
postoperatively.   
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Table 1.  Demographic and clinical data for meningioma patients and univariate analysis of preoperative seizures 
 Total n. of 
patients  
Preoperative seizures   
 
283 
Yes  
N=68 
No  
N=215  
OR (95% CI) P 
Focal-aware 
Motor (%)  16 (23.5) 
   
Non-motor (%) 9 (13.2) 
Focal-impaired awareness (%)  7 (10.3)    
Focal to bilateral (%)  36 (52.9)    
Age at diagnosis (years)      
Mean (SD) 57.7 56.2 (14.1) 58.2 (12.6)  0.410 
Gender (%)      
Female  214 (75.6) 47 (69.1) 167 (77.7)   
Male  69 (24.4) 21 (30.9) 48 (22.3) 1.56 (.85-2.85) 0.152 
WHO grade (%)      
I 233 (82.3) 54 (79.4) 179 (83.3)   
II 47 (16.6) 13 (19.1) 34 (15.8) 1.29 (0.65-2.57) 0.469 
III 3 (1.1) 1 (1.5) 2 (0.9) 1.59 (0.14-17.81) 0.707 
Tumour location (%)      
Non-skull base 207 (73.1) 49 (72.1) 158 (73.5) 0.93 (0.51-1.71) 0.871 
Convexity 98 (34.6) 25 (36.8) 73 (34.0) 1.13 (0.64-1.20) 0.671 
Parafalcine 39 (13.8) 15 (22.1) 24 (11.2) 2.25 (1.10-4.60) 0.023 
Tentorial 24 (8.5) 2 (2.9) 22 (10.2) 0.27 (0.06-1.16) 0.060 
Convexity/parafalcine 17 (6.0) 2 (2.9) 15 (7.0) 0.40 (0.09-1.81) 0.222 
Parasagittal 12 (4.2) 4 (5.9) 8 (3.7) 1.61 (0.47-5.55) 0.441 
Posterior fossa 5 (1.8) 0  5 (2.3) N/A N/A 
Others 12 1 11 N/A N/A 
Skull base 76 (26.9) 19 (27.9) 57 (26.5)   
Sphenoid 34 (12.0) 10 (14.7) 24 (11.2) 1.37 (0.62-3.04) 0.433 
Olfactory groove 18 (6.4) 5 (7.4) 13 (6.0) 1.23 (0.42-3.40) 0.700 
Suprasellar 10 (3.5) 1 (1.5) 9 (4.2) 0.34 (0.04-2.75) 0.290 
Posterior fossa 2 (0.7) 0  2 (0.9) N/A N/A 
Others 12 3 9 N/A N/A 
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Side      
Right 123 (43.5)  36 (52.9) 87 (40.5) 1.66 (0.96-2.86) 0.070 
Left 125 (44.2)  27 (39.7) 98 (45.6) 0.79 (0.45-1.37) 0.395 
Bilateral 35 (12.4)  5 (7.4) 30 (14.0) 0.49 (0.18-1.32) 0.150 
Relation to brain lobes      
Frontal 138 (48.8) 37 (54.4) 101 (47.0) 1.35 (0.78-2.33) 0.285 
Parietal 34 (12.0)  17 (25.0) 17 (7.9) 3.88 (1.85-8.13) <0.001 
Temporal 29 (10.3)  8 (11.8) 21 (9.8) 1.23 (0.52-2.92) 0.636 
Fronto-parietal 16 (5.7) 3 (4.4) 13 (6.0) 0.72 (0.19-2.59) 0.611 
Fronto-temporal 12 (4.2)  0  12 (5.6) N/A N/A 
Occipital 9 (3.2)  1 (1.5) 8 (3.7) 0.39 (0.05-3.14) 0.357 
Preoperative radiological characteristics       
Tumour volume (cm3) † (%)      
Median (IQR) 24.8 (37.8) 28.1 (27.7) 37.2 (39.8)  0.195 
≤10 cm3 57 (20.5) 12 (17.9) 45 (21.3)   
>10 cm3 221 (79.5) 55 (82.1) 166 (78.7) 1.24 (0.61-2.52) 0.546 
Midline shift (%)      
Yes 155 (54.8) 40 (58.8) 115 (53.5) 1.24 (0.72-2.16) 0.441 
No 128 (45.2) 28 (41.2) 100 (46.5)   
Calcification* (%)      
Yes 66 (23.3) 15 (22.1) 51 (23.7)   
No 216 (76.3) 53 (77.9) 163 (75.8) 1.11 (0.57-2.13) 0.815 
Presence of peritumoural signal intensity (%)      
6-100% (present) 158 (55.8) 54 (79.4) 104 (48.4) 4.12 (2.16-7.85) <0.001 
0-5% (absent) 125 (44.2) 14 (20.6) 111 (51.6)   
Preoperative headaches (%)      
Yes 125 (44.2) 26 (38.2) 99 (46.0)   
No 158 (55.8) 42 (61.8) 116 (54.0) 1.38 (0.79-2.41) 0.258 
Preoperative neurological deficits (%)      
Yes 201 (71.0) 33 (48.5) 168 (78.1)   
 
 
 
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 82 (29.0) 35 (51.5) 47 (21.9) 3.79 (2.13-6.74) <0.001 
Preoperative ECOG performance status       
0-2 264 (93.3) 63 (92.6) 201 (93.5)   
3-4 19 (6.7) 5 (7.4) 14 (6.5) 0.71 (0.34-1.51) 0.370 
Abbreviations:  WHO=World Health Organisation; ECOG=Eastern Cooperative Oncology Group. 
* Missing 1 value 
† Missing 5 values 
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Table 2. Analysis of risk factors for postoperative seizures 
 All patients (283) Seizure-naïve patients (n=215) 
 Postoperative seizures Univariate analysis Postoperative seizures Univariate analysis 
Characteristic Yes 
N=48 
No 
N=235 
OR (95% CI) P Yes 
N=29 
No 
N=186 
OR (95% CI) P 
Age at diagnosis (years)         
Mean (SD) 
57.6 
(11.4) 
57.7 (13.3)  0.751 59.0 
(11.9) 
58.1 (12.7)  0.744 
Gender (%)         
Female 31 (64.6) 183 (77.9)   17 (58.6) 150 (80.6)   
Male 17 (35.4) 52 (22.1) 1.93 (0.99-3.76) 0.051 12 (41.4) 36 (19.4) 2.94 (1.29-6.70) 0.008 
WHO grade (%)         
I 39 (81.3) 194 (82.6)   23 (79.3) 156 (83.9)   
II 8 (16.7) 39 (16.6) 1.09 (0.49-2.43) 0.829 6 (20.7) 28 (15.1) 1.36 (0.51-3.61) 0.541 
III 1 (2.1) 2 (0.9) 2.48 (0.22-27.89) 0.462 0  2 (1.1) N/A N/A 
Tumour location (%)         
Non-skull base 37 (77.1) 170 (72.3) 1.29 (0.62-2.67) 0.499 24 (82.8) 134 (72.0) 1.86 (0.67-5.14) 0.224 
Convexity 24 (50.0) 74 (31.5) 2.18 (1.16-4.08) 0.014 17 (58.6) 56 (30.1) 2.83 (1.27-6.34) 0.003 
Parafalcine 10 (20.8) 29 (12.3) 1.87 (0.84-4.15) 0.120 6 (20.7) 18 (9.7) 2.43 (0.87-6.76) 0.080 
Tentorial 1 (2.1) 23 (9.8) 0.20 (0.03-1.49) 0.115 0 22 (11.8) N/A N/A 
Convexity/parafalcine 1 (2.1) 16 (6.8) 0.29 (0.04-2.25) 0.209 0 15 (8.1) N/A N/A 
Parasagittal 1 (2.1) 11 (4.7) 0.43 (0.05-3.44) 0.416 1 (3.4) 7 (3.8) 0.91 (0.11-7.71) 0.934 
Posterior fossa 0  5 (2.1) N/A N/A 0 (0.0) 5 (2.7) N/A N/A 
Others 0 12 N/A N/A 0 11  N/A N/A 
Skull base 11 (22.9) 65 (27.7)   5 (17.2) 52 (28.0)   
Sphenoid 7 (14.6)  27 (11.5) 1.32 (0.54-3.22) 0.548 4 (13.8) 20 (10.8) 1.33 (0.42-4.21) 0.629 
Olfactory groove 1 (2.1) 17 (6.0) 0.27 (0.03-2.10) 0.183 0  13 (7.0) N/A N/A 
Suprasellar 0  10 (4.3) N/A N/A 0  9 (4.8) N/A N/A 
Posterior fossa 0 2 (0.9) (N/A N/A 0 2 (1.1) N/A N/A 
Others 3 9 N/A N/A 1 8 N/A N/A 
Side         
Right 20 (41.7) 103 (43.8) 0.92 (0.49-1.72) 0.783 10 (34.5) 77 (41.4) 0.75 (0.33-1.69) 0.480 
Left 26 (54.2) 99 (42.1) 1.62 (0.87-3.03) 0.126 18 (62.1) 80 (43.0) 2.17 (0.97-4.85) 0.059 
Bilateral 2 (4.2) 33 (14.0) 0.27 (0.06-1.15) 0.058 1 (3.4) 29 (15.6) 0.19 (0.03-1.48) 0.113 
 
 
 
28 
 
Relation to brain lobes         
Frontal 25 (52.1) 113 (48.1) 1.18 (0.63-2.18) 0.614 16 (55.2) 85 (36.2) 1.46 (0.67-3.21) 0.342 
Parietal 5 (10.4) 29 (12.3) 0.83 (0.30-2.26) 0.709 1 (3.4) 16 (8.6) 0.38 (0.05-2.98) 0.339 
Temporal 7 (14.6) 22 (9.4) 1.65 (0.66-4.12) 0.277 4 (13.8) 17 (9.1) 1.59 (0.50-5.11) 0.432 
Fronto-parietal 7 (14.6) 9 (3.9) 4.35 (1.52-12.50) 0.003 6 (20.7) 7 (3.7) 6.67 (2.06-21.57) <0.001 
Fronto-temporal 1 (2.1) 11 (4.7) 0.43 (0.05-3.44) 0.416 1 (3.4) 11 (5.9) 0.57 (0.07-4.57) 0.591 
Occipital 0  9 (3.3) N/A N/A 0 8 (4.3) N/A N/A 
Preoperative radiological 
characteristics  
      **  
Tumour volume (cm3) § (%)         
Median (IQR) 
47.5 
(56.3) 
32.5 (35.4)  0.060 63.3 
(70.3) 
33.2 (36.6)  0.003 
≤10 cm3 6 (12.8) 51 (22.6)   3 (10.7) 42 (23.0)   
>10 cm3 41 (87.2) 180 (77.9) 1.94 (0.78-4.82) 0.149 25 (89.3) 141 (77.0) 2.48 (0.71-8.63) 0.141 
Midline shift (%)         
Yes 30 (62.5) 125 (53.2) 1.47 (0.78-2.77) 0.238 21 (72.4) 94 (50.5) 2.56 (1.09-6.25) 0.028 
No 18 (37.5) 110 (46.8)   8 (27.6) 92 (49.5)   
Calcification* (%)         
Yes 13 (27.1) 53 (22.6)   9 (31.0) 42 (22.6)   
No 34 (70.8) 182 (77.4) 0.76 (0.38-1.55) 0.450 19 (65.5) 144 (77.4) 0.62 (0.26-1.46) 0.268 
Presence of peritumoural signal 
intensity (%) 
        
6-100% (present) 34 (70.8) 124 (52.8) 2.17 (1.11-4.35) 0.022 20 (69.0) 84 (45.2) 2.70 (1.16-6.25) 0.017 
0-5% (absent) 14 (29.2) 111 (47.2)   9 (31.0) 102 (54.8)   
Preoperative headaches (%)         
Yes 17 (35.4) 108 (46.0) 
  
12 (41.4) 87 (46.8)   
No 31 (64.6) 127 (54.0) 1.55 (0.81-2.95) 0.180 17 (58.6) 99 (53.2) 1.24 (0.56-2.75) 0.588 
Preoperative neurological 
deficits (%) 
        
Yes 30 (62.5) 175 (74.5)   24 (82.8) 144 (77.4)   
No 18 (37.5) 60 (25.5) 1.75 (0.91-3.37) 0.093 5 (17.2) 42 (22.6) 0.71 (0.26-1.99) 0.518 
Preoperative ECOG performance 
status (%) 
        
0-2 44 (91.7) 220 (93.6)   26 (89.7) 175 (94.1)   
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3-4 4 (8.3) 15 (6.4) 1.41 (0.66-2.99) 0.373 3 (10.3) 11 (5.9) 2.09 (0.87-4.99) 0.093 
Simpson grade of resection (%)         
GTR 42 (87.5) 191 (81.3) 1.61 (0.65-4.03) 0.303 26 (89.7) 150 (80.6) 2.08 (0.59-7.25) 0.242 
1 16 (33.3) 49 (20.9) 1.95 (0.98-3.84) 0.054 11 (37.9) 36 (19.4) 2.63 (1.14-5.88) 0.020 
2 24 (50.0) 129 (54.9) 0.82 (0.44-1.53) 0.535 15 (51.7) 103 (55.4) 0.86 (0.39-1.89) 0.713 
3 2 (4.2) 13 (5.5) 0.75 (0.16-3.40) 0.701 0 11 (5.9) N/A N/A 
STR 6 (12.5) 44 (18.7)   3 (10.3) 36 (19.4)   
4 6 (12.5) 44 (18.7)   3 (10.3) 36 (19.4)   
5 0 0 N/A N/A 0 0 N/A N/A 
Postoperative residual tumour‡ 
(%)  
        
Yes 7 (14.9) 43 (18.5)   3 (10.7) 32 (17.3)   
No 40 (85.1) 189 (81.5) 1.30 (0.55-3.10) 0.554 25 (89.3) 153 (82.7) 1.74 (0.50-6.12) 0.381 
Postoperative neurosurgical 
complications ‡ (%) 
        
Yes  28 (58.3) 110 (46.8) 1.63 (0.86-3.09) 0.128 19 (65.5) 91 (48.9) 1.94 (0.86-4.40) 0.108 
No 19 (39.6) 122 (51.9)   10 (34.5) 93 (50.0)   
Radiological hematoma ‡    .^      
Yes 27 (56.3) 104 (44.3) 1.66 (0.88-3.13) 0.114 18 (62.1) 85 (45.7) 1.91 (0.85-4.26) 0.112 
No 20 (41.7) 128 (54.5)   11 (37.9) 99 (53.2)   
Clinical hematoma          
Yes 4 (8.3) 11 (4.7) 1.85 (0.56-6.08) 0.303 4 (13.8) 8 (4.3) 3.57 (1.00-12.50) 0.038 
No 44 (91.7) 224 (95.3)   25 (86.2) 178 (95.7)   
CNS infection          
Yes 4 (8.3) 9 (3.8) 2.28 (0.67-7.74) 0.174 4 (13.8) 9 (4.8) 3.15 (0.90-10.98) 0.072 
No 44 (91.7) 226 (96.2)   25 (86.2) 177 (95.2)   
Hydrocephalus          
Yes 1 (2.1) 5 (2.1) 0.98 (0.11-8.57) 0.985 1 (3.4) 5 (2.7) 1.29 (0.15-11.48) 0.817 
No 47 (97.9) 230 (97.9)   28 (96.6) 181 (97.3)   
Preoperative Seizures (%)         
Yes 19 (39.6) 49 (20.9) 2.50 (1.28-4.76) 0.006 0 0 N/A N/A 
No 29 (60.4) 186 (79.1)   29 (100) 186 (100)   
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Abbreviations: WHO=World Health Organisation; ECOG=Eastern Cooperative Oncology Group; GTR=gross total resection; STR=subtotal 
resection.  
* Missing 1 value 
† Missing 3 values 
‡ Missing 4 values  
§ Missing 5 values  
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Table 3. Cox regression model results  
Model  Factor HR (95% CI)  P 
whole study population Preoperative AED 0.62 (0.31-1.26) 0.187 
Convexity * FP * preoperative seizures 1.06 (1.02-1.10) 0.004 
Seizure-naïve patients  Preoperative AED 0.63 (0.20-2.05) 0.451 
Convexity * FP * midline shift  1.04 (1.01-1.06) 0.002 
Abbreviations: FP=fronto-parietal location 
* By  
 
